Enzolytics Inc. (ENZC)
USD 0.0
(7.69%)
USD 0.0
(7.69%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 361.7 Million USD | 15846.97% |
| 2022 | 2.26 Million USD | -29.96% |
| 2021 | 3.23 Million USD | 469.7% |
| 2020 | 568.41 Thousand USD | -89.85% |
| 2019 | 5.59 Million USD | -0.27% |
| 2018 | 5.61 Million USD | 69.68% |
| 2017 | 3.3 Million USD | 5883.14% |
| 2016 | 55.29 Thousand USD | -91.42% |
| 2015 | 644.17 Thousand USD | 0.0% |
| 2010 | 152.93 Thousand USD | 79.21% |
| 2009 | 85.33 Thousand USD | -21.3% |
| 2008 | 108.42 Thousand USD | -21.95% |
| 2007 | 138.92 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 201.68 Million USD | -44.24% |
| 2024 Q1 | 361.69 Million USD | 0.0% |
| 2023 Q2 | 2.46 Million USD | 32.33% |
| 2023 FY | 361.7 Million USD | 15846.97% |
| 2023 Q3 | 1.8 Million USD | -26.89% |
| 2023 Q1 | 1.86 Million USD | -17.77% |
| 2022 Q2 | 2.17 Million USD | -30.58% |
| 2022 Q4 | 2.26 Million USD | 15.8% |
| 2022 FY | 2.26 Million USD | -29.96% |
| 2022 Q3 | 1.95 Million USD | -10.14% |
| 2022 Q1 | 3.13 Million USD | 0.0% |
| 2021 Q1 | 21.72 Million USD | 1.06% |
| 2021 FY | 3.23 Million USD | 469.7% |
| 2021 Q2 | 22.74 Million USD | 4.7% |
| 2021 Q3 | 22.36 Million USD | -1.68% |
| 2020 Q4 | 21.49 Million USD | 0.0% |
| 2020 FY | 568.41 Thousand USD | -89.85% |
| 2019 FY | 5.59 Million USD | -0.27% |
| 2018 FY | 5.61 Million USD | 69.68% |
| 2017 FY | 3.3 Million USD | 5883.14% |
| 2016 FY | 55.29 Thousand USD | -91.42% |
| 2015 FY | 644.17 Thousand USD | 0.0% |
| 2011 Q1 | 136.89 Thousand USD | -10.49% |
| 2011 Q2 | 112.05 Thousand USD | -18.15% |
| 2010 Q4 | 152.93 Thousand USD | -89.13% |
| 2010 Q1 | 75.42 Thousand USD | -11.62% |
| 2010 FY | 152.93 Thousand USD | 79.21% |
| 2010 Q3 | 1.4 Million USD | 3.89% |
| 2010 Q2 | 1.35 Million USD | 1696.32% |
| 2009 FY | 85.33 Thousand USD | -21.3% |
| 2009 Q4 | 85.33 Thousand USD | -29.73% |
| 2009 Q3 | 121.44 Thousand USD | -18.59% |
| 2009 Q2 | 149.16 Thousand USD | 4.66% |
| 2009 Q1 | 142.53 Thousand USD | 31.45% |
| 2008 Q1 | 38.64 Thousand USD | -72.18% |
| 2008 Q4 | 108.42 Thousand USD | 1.2% |
| 2008 Q3 | 107.14 Thousand USD | 47.69% |
| 2008 Q2 | 72.54 Thousand USD | 87.72% |
| 2008 FY | 108.42 Thousand USD | -21.95% |
| 2007 Q4 | 138.92 Thousand USD | 12763.06% |
| 2007 Q3 | 1080.00 USD | 0.0% |
| 2007 FY | 138.92 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -15658194.762% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -18371.486% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -3327.199% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -65412.318% |
| Rebus Holdings, Inc. | 5000.00 USD | -7234032.18% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -177.786% |
| Qrons Inc. | 420.00 USD | -86120521.19% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -46835.629% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -1194.398% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -75168.201% |
| Skye Bioscience, Inc. | 11.94 Million USD | -2929.264% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -831.106% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -4909.952% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -473623.196% |
| SQZ Biotechnologies Company | 107.18 Million USD | -237.454% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -25158.277% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -499736.397% |
| Mesoblast Limited | 667.9 Million USD | 45.844% |
| Marizyme, Inc. | 22.01 Million USD | -1542.995% |
| Genus plc | 1.02 Billion USD | 64.845% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -26528.322% |
| Pharming Group N.V. | 462.85 Million USD | 21.853% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -10817.757% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -72380.63% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -57588.454% |
| ContraFect Corporation | 20.67 Million USD | -1649.149% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -92558.328% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -94543.741% |
| IMV Inc. | 31.33 Million USD | -1054.366% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -8624.185% |
| MultiCell Technologies, Inc. | 126.22 USD | -286568279.813% |
| ONE Bio Corp. | 70.08 Million USD | -416.093% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -38392.162% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -181.462% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -83683.85% |
| Q BioMed Inc. | 3.51 Million USD | -10188.86% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -928.189% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -138337.983% |
| Biomind Labs Inc. | 73.81 Thousand USD | -489891.207% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 18.956% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -24865.204% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -1105.088% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -13070.52% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -52512.942% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -13794.713% |
| GB Sciences, Inc. | 103.44 Thousand USD | -349570.935% |
| Alpha Cognition Inc. | 2.45 Million USD | -14650.47% |
| HST Global, Inc. | 1526.00 USD | -23702823.263% |
| CSL Limited | 38.02 Billion USD | 99.049% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -36511.204% |
| Halberd Corporation | 10.13 Thousand USD | -3570195.223% |
| Agentix Corp. | 261.39 Thousand USD | -138277.077% |
| Resverlogix Corp. | 8.11 Million USD | -4357.26% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -19161.434% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 92.037% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -658.263% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -56447.052% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1587655.625% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -3941.796% |
| AVAX Technologies, Inc. | 7.37 Million USD | -4803.062% |
| Zenith Capital Corp. | 7410.00 USD | -4881230.756% |
| Genscript Biotech Corporation | 3.38 Billion USD | 89.319% |
| Ember Therapeutics, Inc. | 184.00 USD | -196579578.804% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -112298.964% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -138291.901% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -38878.643% |
| Kadimastem Ltd | 2.3 Million USD | -15598.526% |
| Helix BioMedix, Inc. | 3.02 Million USD | -11856.903% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -586.337% |
| BioStem Technologies, Inc. | 14.56 Million USD | -2384.199% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -633428.232% |
| LadRx Corporation | 2.3 Million USD | -15572.665% |
| Cell Source, Inc. | 195.17 Thousand USD | -185228.05% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -102187.675% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -102187.675% |
| NovAccess Global Inc. | 62.24 Thousand USD | -580973.463% |
| Affymax, Inc. | 7.44 Million USD | -4759.688% |
| Itoco Inc. | 1.4 Million USD | -25734.858% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -378028.74% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -341132.65% |
| Mobile Lads Corp. | 52.00 USD | -695589532.692% |
| CytoDyn Inc. | 11.13 Million USD | -3148.084% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -252891.221% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -2022867.612% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -93734.973% |
| SYBLEU INC | 330.46 Thousand USD | -109352.839% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -88245.67% |
| International Stem Cell Corporation | 5.39 Million USD | -6610.698% |
| Bioxytran, Inc. | 137.63 Thousand USD | -262695.601% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -2311.083% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -2081.715% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -457756.467% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -41731.413% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -4711.848% |
| Neutra Corp. | 2851.00 USD | -12686908.383% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -1016.172% |
| PureTech Health plc | 693.97 Million USD | 47.879% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -4381.509% |
| IXICO plc | 15.84 Million USD | -2182.939% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -4267.382% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -250.07% |
| CSL Limited | 38.02 Billion USD | 99.049% |
| Cellectis S.A. | 333.99 Million USD | -8.297% |